Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 17.5% in July

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 47,100 shares, a decline of 17.5% from the June 30th total of 57,100 shares. Currently, 10.7% of the shares of the stock are sold short. Based on an average trading volume of 32,200 shares, the days-to-cover ratio is currently 1.5 days.

Windtree Therapeutics Price Performance

NASDAQ WINT opened at $8.29 on Monday. The company’s 50-day simple moving average is $3.57 and its 200 day simple moving average is $5.53. Windtree Therapeutics has a twelve month low of $2.81 and a twelve month high of $30.06.

Windtree Therapeutics (NASDAQ:WINT) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($9.25) earnings per share for the quarter. On average, equities research analysts forecast that Windtree Therapeutics will post -2.38 EPS for the current year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.